Andere Sprachen Processa Pharmaceuticals, Inc.

Aktien

A40161

US74275C3043

PCSA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 10.06.2024			% 5 Tage	% 1. Jan.
1,58 ^USD	-4,24 %		-1,25 %	-76,39 %

07.06.	Top Absteiger vorbörslich	MT
10.05.	Processa Pharmaceuticals, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Top Premarket Decliners	07.06.
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10.05.
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference	06.05.
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research	30.04.
Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research	30.04.
Certain Common Warrants of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	30.04.
Certain Restricted Stock Units of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	30.04.
Certain Options of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	30.04.
Certain Common Stock of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	30.04.
Top Premarket Decliners	26.04.
Top Midday Gainers	25.04.
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial	11.04.
Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial	11.04.
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference	28.03.
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting	25.03.
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference	21.02.
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference	14.02.
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule	06.02.
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Processa Pharmaceuticals, Inc.

Aktien

A40161

US74275C3043

PCSA

Andere Sprachen

Filter